New onset and exacerbations of psoriasis following COVID-19 vaccines: a systematic review
Background Vaccination has been promoted to control viral transmission in response to the
coronavirus disease 2019 (COVID-19) pandemic. Cases of new-onset or exacerbation of …
coronavirus disease 2019 (COVID-19) pandemic. Cases of new-onset or exacerbation of …
The importance of measuring SARS-CoV-2-specific T-cell responses in an ongoing pandemic
Neutralizing antibodies are considered a correlate of protection against SARS-CoV-2
infection and severe COVID-19, although they are not the only contributing factor to …
infection and severe COVID-19, although they are not the only contributing factor to …
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions …
A Abhishek, RJ Boyton, N Peckham… - The Lancet …, 2022 - thelancet.com
Background Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-
CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately …
CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately …
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the …
Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients
M Oyaert, MA De Scheerder, S Van Herrewege… - Frontiers in …, 2022 - frontiersin.org
Background Immunocompromised patients are at increased risk of severe COVID-19 and
impaired vaccine response. In this observational prospective study, we evaluated …
impaired vaccine response. In this observational prospective study, we evaluated …
Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study
M Shrotri, E Fragaszy, V Nguyen… - Nature …, 2022 - nature.com
Vaccination constitutes the best long-term solution against Coronavirus Disease-2019;
however, vaccine-derived immunity may not protect all groups equally, and the durability of …
however, vaccine-derived immunity may not protect all groups equally, and the durability of …
[HTML][HTML] Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
RM Dayam, JC Law, RL Goetgebuer, GYC Chao… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Limited information is available on the impact of immunosuppressants on
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions
M Krasselt, U Wagner, P Nguyen, C Pietsch… - …, 2022 - academic.oup.com
Objectives Successful vaccination is key to overcoming the COVID-19 pandemic.
Immunosuppressive medication is known to potentially compromise vaccination responses …
Immunosuppressive medication is known to potentially compromise vaccination responses …
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic
A Zaccardelli, ZS Wallace… - Current opinion in …, 2023 - journals.lww.com
Although COVID-19 outcomes have improved over the pandemic for patients with RA, some
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …
Evaluation of humoral and cellular immune responses to the SARS-CoV-2 vaccine in patients with common variable immunodeficiency phenotype and patient …
A Antolí, G Rocamora-Blanch, M Framil… - Frontiers in …, 2022 - frontiersin.org
Introduction SARS-CoV-2 vaccines' effectiveness is not yet clearly known in
immunocompromised patients. This study aims to assess the humoral and cellular specific …
immunocompromised patients. This study aims to assess the humoral and cellular specific …